{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:08:23Z","timestamp":1782623303384,"version":"3.54.5"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.metabol.2025.156297","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:36:11Z","timestamp":1747121771000},"page":"156297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Use of finerenone in patients with chronic kidney disease at high risk of heart failure"],"prefix":"10.1016","volume":"169","author":[{"given":"John P.","family":"Hakim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trina","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2025.156297_bb0005","doi-asserted-by":"crossref","first-page":"e05","DOI":"10.15420\/ecr.2021.52","article-title":"Arrhythmias in chronic kidney disease","volume":"17","author":"Akhtar","year":"2022","journal-title":"Eur Cardiol"},{"issue":"14","key":"10.1016\/j.metabol.2025.156297_bb0010","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease: JACC state-of-the-art review","volume":"74","author":"Sarnak","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.metabol.2025.156297_bb0015","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/ndt\/gfz232","article-title":"Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies","volume":"36","author":"Pickup","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12933-023-01869-6","article-title":"Rapid kidney function decline and increased risk of heart failure in patients with type 2 diabetes: findings from the ACCORD cohort: rapid kidney function decline and heart failure in T2D","volume":"22","author":"Bueno Junior","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2025.156297_bb0025","first-page":"dc210431","article-title":"Identification and predictors for cardiovascular disease risk equivalents among adults with diabetes mellitus","author":"Zhao","year":"2021","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.metabol.2025.156297_bb0030","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2025.156297_bb0035","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.metabol.2025.156297_bb0040","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.metabol.2025.156297_bb0045","author":"Food and Drug Administration"},{"issue":"23","key":"10.1016\/j.metabol.2025.156297_bb0050","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.metabol.2025.156297_bb0055","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.metabol.2025.156297_bb0060","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2025.156297_bb0065","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.metabol.2025.156297_bb0070","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.metabol.2025.156297_bb0075","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.metabol.2025.156297_bb0080","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.metabol.2025.156297_bb0085","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.xkme.2023.100624","article-title":"All-cause and cardiovascular-related mortality in CKD patients with and without heart failure: a population-based cohort study in Kaiser Permanente Southern California","volume":"5","author":"Yu","year":"2023","journal-title":"Kidney Med."},{"issue":"3","key":"10.1016\/j.metabol.2025.156297_bb0090","first-page":"251","article-title":"Cardiorenal syndrome: pathophysiology","volume":"37","author":"Kumar","year":"2019","journal-title":"Cardiol Clin"},{"issue":"2","key":"10.1016\/j.metabol.2025.156297_bb0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2023.04.052","article-title":"Cardiovascular outcomes in patients with diabetes and kidney disease: JACC review topic of the week","volume":"82","author":"Morales","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.metabol.2025.156297_bb0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.metabol.2025.156297_bb0105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.metabol.2025.156297_bb0110","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0115","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-14-0471","article-title":"Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals","volume":"224","author":"Young","year":"2015","journal-title":"J Endocrinol"},{"issue":"3","key":"10.1016\/j.metabol.2025.156297_bb0120","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/j.2040-4603.2014.tb00569.x","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"issue":"2","key":"10.1016\/j.metabol.2025.156297_bb0125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.metabol.2025.156297_bb0130","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.metabol.2025.156297_bb0135","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.metabol.2025.156297_bb0140","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"issue":"36","key":"10.1016\/j.metabol.2025.156297_bb0145","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.metabol.2025.156297_bb0150","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0155","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/07853890.2023.2171110","article-title":"Cardiorenal benefits of finerenone: protecting kidney and heart","volume":"55","author":"Gonz\u00e1lez-Juanatey","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.metabol.2025.156297_bb0160","unstructured":"NIH. PubChem for spironolactone."},{"key":"10.1016\/j.metabol.2025.156297_bb0165","unstructured":"NIH. PubChem for eplerenone."},{"key":"10.1016\/j.metabol.2025.156297_bb0170","unstructured":"NIH, PubChem for finerenone."},{"issue":"8","key":"10.1016\/j.metabol.2025.156297_bb0175","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1016\/j.metabol.2025.156297_bb0180","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.metabol.2025.156297_bb0185","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"39","key":"10.1016\/j.metabol.2025.156297_bb0190","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2025.156297_bb0195","author":"Food and Drug Administration"},{"key":"10.1016\/j.metabol.2025.156297_bb0200","author":"Food and Drug Administration"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0205","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.metabol.2025.156297_bb0210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cpt1976192177","article-title":"Spironolactone. III. Canrenone\u2013maximum and minimum steady-state plasma levels","volume":"19","author":"Karim","year":"1976","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.metabol.2025.156297_bb0215","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.metabol.2025.156297_bb0220","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.metabol.2025.156297_bb0225","doi-asserted-by":"crossref","first-page":"101190","DOI":"10.1016\/j.diabet.2020.08.005","article-title":"Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: data from the MIRAD trial","volume":"47","author":"Brandt-Jacobsen","year":"2021","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2025.156297_bb0230","doi-asserted-by":"crossref","first-page":"6683987","DOI":"10.1155\/2023\/6683987","article-title":"Efficacy and safety of eplerenone for treating chronic kidney disease: a meta-analysis","volume":"2023","author":"Hu","year":"2023","journal-title":"Int J Hypertens"},{"issue":"12","key":"10.1016\/j.metabol.2025.156297_bb0235","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.metabol.2025.156297_bb0240","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.metabol.2025.156297_bb0245","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","article-title":"Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial","volume":"56","author":"Saklayen","year":"2008","journal-title":"J Invest Med"},{"issue":"12","key":"10.1016\/j.metabol.2025.156297_bb0250","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.metabol.2025.156297_bb0255","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3109\/08860220903216121","article-title":"Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease","volume":"31","author":"Sengul","year":"2009","journal-title":"Ren Fail"},{"issue":"9","key":"10.1016\/j.metabol.2025.156297_bb0260","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.metabol.2025.156297_bb0265","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2025.156297_bb0270","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.2337\/dc24-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes\u20132024","volume":"47","author":"American Diabetes Association professional practice committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"5S","key":"10.1016\/j.metabol.2025.156297_bb0275","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving global outcomes diabetes work group","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0280","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"Authors\/Task Force Members","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.metabol.2025.156297_bb0290","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.metabol.2025.156297_bb0295","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.metabol.2025.156297_bb0300","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0305","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.metabol.2025.156297_bb0310","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"10.1016\/j.metabol.2025.156297_bb0315","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution set Oversight Committee","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0320","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.metabol.2025.156297_bb0325","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.metabol.2025.156297_bb0330","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.metabol.2025.156297_bb0335","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD Trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.metabol.2025.156297_bb0340","doi-asserted-by":"crossref","first-page":"e006260","DOI":"10.1161\/CIRCOUTCOMES.119.006260","article-title":"Type 2 diabetes mellitus and impact of heart failure on prognosis compared to other cardiovascular diseases: a nationwide study","volume":"13","author":"Zareini","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.metabol.2025.156297_bb0345","doi-asserted-by":"crossref","first-page":"100739","DOI":"10.1016\/j.eclinm.2021.100739","article-title":"Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years","volume":"32","author":"Lawson","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"31","key":"10.1016\/j.metabol.2025.156297_bb0350","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"27","key":"10.1016\/j.metabol.2025.156297_bb0355","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.metabol.2025.156297_bb0360","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.111.020982","article-title":"Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study","volume":"123","author":"Alonso","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0365","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2337\/dbi19-0038","article-title":"Linking kidney and cardiovascular complications in diabetes-impact on prognostication and treatment: the 2019 Edwin Bierman award lecture","volume":"70","author":"Rossing","year":"2021","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.metabol.2025.156297_bb0370","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"issue":"10458","key":"10.1016\/j.metabol.2025.156297_bb0375","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.metabol.2025.156297_bb0380","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s11255-022-03432-w","article-title":"Effect of finerenone on cardiovascular events in kidney disease and\/or diabetes: a meta analysis of randomized control trials","volume":"55","author":"Zhu","year":"2023","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"10.1016\/j.metabol.2025.156297_bb0385","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.metabol.2025.156297_bb0390","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0395","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ehjcvp\/pvac054","article-title":"Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease","volume":"9","author":"Filippatos","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0400","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5582\/irdr.2020.01008","article-title":"The cardiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"11","author":"Abdelazeem","year":"2022","journal-title":"Intractable Rare Dis Res"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0405","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2025.156297_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.03.006","article-title":"Finerenone across the spectrum of kidney risk in heart failure: the FINEARTS-HF trial","author":"Ostrominski","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.metabol.2025.156297_bb0415","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-8587(24)00309-7","article-title":"Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial","volume":"13","author":"Butt","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.metabol.2025.156297_bb0420","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 3","key":"10.1016\/j.metabol.2025.156297_bb0425","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/ndt\/gfz206","article-title":"Hyperkalemia: pathophysiology, risk factors and consequences","volume":"34","author":"Hunter","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.metabol.2025.156297_bb0430","first-page":"1801","article-title":"Studies on organ- and subcellular distribution of 3 H-spironolactone in animals","volume":"22","author":"Platt","year":"1972","journal-title":"Arzneimittelforschung"},{"issue":"10","key":"10.1016\/j.metabol.2025.156297_bb0435","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan\u20132022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0440","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ndt\/gfz285","article-title":"Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: comparative results from an open-label, phase 3 study","volume":"36","author":"Roger","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"41","key":"10.1016\/j.metabol.2025.156297_bb0445","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.metabol.2025.156297_bb0450","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ndt\/gfad026","article-title":"SGLT2 inhibitors: new kids on the block to control hyperkalemia","volume":"38","author":"Gabai","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.metabol.2025.156297_bb0455","author":"CPC Clinical Research & CPC Community Health"},{"issue":"12","key":"10.1016\/j.metabol.2025.156297_bb0460","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.metabol.2025.156297_bb0465","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.recesp.2021.10.016","volume":"75","author":"Visseren","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"1","key":"10.1016\/j.metabol.2025.156297_bb0470","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/dom.15997","article-title":"Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States","volume":"27","author":"Zheng","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2025.156297_bb0475","first-page":"e243782","article-title":"Estimated long-term benefits of finerenone in heart failure: a prespecified secondary analysis of the FINEARTS-HF randomized clinical trial","author":"Vaduganathan","year":"2024","journal-title":"JAMA Cardiol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525001660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525001660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:42:55Z","timestamp":1762213375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049525001660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":95,"alternative-id":["S0026049525001660"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156297","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of finerenone in patients with chronic kidney disease at high risk of heart failure","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156297"}}